Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Fish and Richardson
Fuji
Daiichi Sankyo
Accenture
Harvard Business School
Deloitte
Colorcon
Boehringer Ingelheim
AstraZeneca

Generated: October 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,871,810

« Back to Dashboard

Claims for Patent: 8,871,810

Title:Treating critically ill patients with intravenous ibuprofen
Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
Inventor(s): Pavliv; Leo (Cary, NC), Rock; Amy Dix (Nashville, TN)
Assignee: Cumberland Pharmaceuticals Inc. (Nashville, TN)
Application Number:12/646,499
Patent Claims: 1. A method of treating pain in critically ill patients in need thereof, comprising administering to critically ill patients an intravenous ibuprofen pharmaceutical composition in a dose of about 800 mg and providing a mean Cmax of about 60 .mu.g/ml to treat pain in said patients, wherein the critically ill patients are not suffering from inflammation and are receiving at least one treatment selected from vasopressor support and mechanical ventilation.

2. The method of claim 1 wherein the pharmaceutical composition is an aqueous solution of arginine and ibuprofen.

3. The method of claim 1, wherein the molar ratio of arginine to ibuprofen is selected from less than or equal to 1:1, less than or equal to 0.99:1, less than or equal to 0.98:1, less than or equal to 0.97:1, less than or equal to 0.96:1, less than or equal to 0.95:1, less than or equal to 0.94:1, less than or equal to 0.93:1, less than or equal to 0.92:1, less than or equal to 0.91:1, less than or equal to 0.90:1, less than or equal to 0.60:1.

4. A method of treating pain in critically ill patients in need thereof, comprising administering to critically ill patients who are in pain, not suffering from inflammation and are selected from the group consisting of patients who are being administered large volumes of blood products; are receiving multiple antibiotics; have a pulmonary artery catheter or an arterial blood pressure catheter inserted; and combinations of any of the foregoing, an intravenous ibuprofen pharmaceutical composition in a dose of 800 mg such that the dose reduces pain in the critically ill patients.

5. The method of claim 4, wherein the dose of intravenous ibuprofen administered to the critically ill patients provides a mean Cmax of about 60 .mu.g/ml.

6. The method of claim 5, wherein the dose of intravenous ibuprofen administered provides a mean (AUC)0-t within about 80% to about 125% of 94 .mu.g.h/ml.

7. The method of claim 4, further comprising selecting a dosage interval for the critically ill patients from dosing intervals of greater than 4 hours and greater than 6 hours.

8. The method of claim 4, further comprising administering the pharmaceutical composition as an aqueous solution of arginine and ibuprofen.

9. The method of claim 8, wherein the molar ratio of arginine to ibuprofen is selected from less than or equal to 1:1, less than or equal to 0.99:1, less than or equal to 0.98:1, less than or equal to 0.97:1, less than or equal to 0.96:1, less than or equal to 0.95:1, less than or equal to 0.94:1, less than or equal to 0.93:1, less than or equal to 0.92:1, less than or equal to 0.91:1, less than or equal to 0.90:1, less than or equal to 0.60:1.

10. The method of claim 1, wherein the critically ill patients are patients who: are being treated in an Intensive Care Unit; are being administered large volumes of blood products; are undergoing dialysis; are receiving multiple antibiotics; have a pulmonary artery catheter or an arterial blood pressure catheter inserted; and combinations of any of the foregoing.

11. The method of claim 1, further comprising selecting a dosage interval for the critically ill patients of every 4 to 6 hours.

12. The method of claim 4, further comprising selecting a dosage interval for the critically ill patients of every 4 to 6 hours.

13. The method of claim 1, further comprising selecting a dosage interval for the critically ill patients from dosing intervals of greater than 4 hours and greater than 6 hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Chubb
Farmers Insurance
Colorcon
Fish and Richardson
Cantor Fitzgerald
Deloitte
Merck
Medtronic
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot